drugset / Trial / NCT06929325
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, multicenter phase III clinical study to evaluate the efficacy and safety of sirolimus for injection (albumin-bound) combined with fulvestrant in patients with HR+ and HER2- advanced breast cancer.
Timeline
- Start
- 2025-04
- Primary completion
- 2026-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | — | Intravenous |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |